Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected well below prior expectations. Read why EBS stock is rated hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results